首页 | 本学科首页   官方微博 | 高级检索  
检索        

正清风痛宁缓释片联合甲氨蝶呤治疗类风湿性关节炎临床观察
引用本文:马海侠,梁先红.正清风痛宁缓释片联合甲氨蝶呤治疗类风湿性关节炎临床观察[J].中国中医药现代远程教育,2020(4):112-114.
作者姓名:马海侠  梁先红
作者单位:中国人民解放军联勤保障部队第九六七医院中医二科;中国人民解放军联勤保障部队第九六七医院康复科
摘    要:目的探讨正清风痛宁缓释片联合甲氨蝶呤治疗类风湿关节炎,对其临床效果及相关炎性指标进行观察。并随机选类风湿关节炎应用甲氨蝶呤联合非甾体止痛药双氯芬酸钠缓释片治疗,2组治疗前后进行对照。方法类风湿关节炎(RA)80例分为:治疗组:40例,甲氨蝶呤7.5 mg/周(补充叶酸5 mg/周),正清风痛宁缓释片60 mg/次,日2次饭后口服。对照组:40例,甲氨蝶呤片12.5 mg/周(补充叶酸5 mg/周),双氯芬酸钠缓释片75 mg/d(饭后口服,联合胃粘膜保护药瑞巴派特,1个月后逐渐减停),12周为1个疗程。2组治疗前及治疗后第4,8,12周对临床疗效及ESR,C-RP进行观察统计。结果治疗组在第4,8,12周均明显优于对照组。P<0.05.尤其在第4周更为明显。经过12周治疗,2组在关节肿胀数、关节疼痛数、关节压痛数、关节晨僵时间及ESR、C-RP检验方面比均有显著差异P<0.05,本组治疗前后比较差异显著P<0.05。2组间治疗效果(有效率)分别为100%、80%。

关 键 词:正清风痛宁缓释片  甲氨蝶呤  类风湿  关节炎  痹证

Clinical Observation on Zhengqing Fengtongning Sustained-Release Tablets Combined with Methotrexate in the Treatment of Rheumatoid Arthritis
MA Haixia,LIANG Xianhong.Clinical Observation on Zhengqing Fengtongning Sustained-Release Tablets Combined with Methotrexate in the Treatment of Rheumatoid Arthritis[J].Chinese Medicine Modern Distance Education of China,2020(4):112-114.
Authors:MA Haixia  LIANG Xianhong
Institution:(Department of Rheumatology and Immunology of Traditional Chinese Medicine,967 Hospital of Joint Logistics Support Force,Liaoning Province,Dalian 116000,China;Rehabilitation Department,967 Hospital of Joint Logistics Support Force,Liaoning Province,Dalian 116000,China)
Abstract:Objective To observe the clinical effect and related inflammatory indexes of Zhengqing Fengtongning sustained-release tablets combined with methotrexate in the treatment of rheumatoid arthritis.Methotrexate combined with diclofenac sodium sustainedrelease tablets were randomly selected for the treatment of rheumatoid arthritis.The two groups were compared before and after treatment.Methods 80 cases of rheumatoid arthritis were divided into two groups.The treatment group of 40 cases was given methotrexate 7.5 mg/week(folic acid 5 mg/week),Zhengqingfengtongning sustained-release tablets 60 mg/time,oral twice a day after meals.The control group of 40 cases was given methotrexate tablets 12.5 mg/week(folic acid 5 mg/week),diclofenac sodium sustained-release tablets 75 mg/day(oral after meals,combined with gastric mucosal protective drug Rebate,gradually stopped after 1 month),12 weeks as a course of treatment.The clinical efficacy and ESR,C-RP was observed and counted before treatment and 4,8 and 12 weeks after treatment.Results The treatment group was better than the control group in 4,8 and 12 weeks P<0.05,especially in the fourth week.After 12 weeks of treatment,there were significant differences in the number of joint swelling,joint pain,joint tenderness,joint morning stiffness time and ESR,C-RP test between the two groups(P<0.05),and there were significant differences before and after treatment(P<0.05).The curative effect(effective rate)of the two groups was 100%and 80%respectively.
Keywords:Zhengqing Fengtongning sustained-release tablets  methotrexate  rheumatoid  arthritis  bi syndrome
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号